Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.…
Perrigo to Attend the Jefferies Miami Consumer Conference
Perrigo Company (NYSE: PRGO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 8,100 employees.
The shares were at 15.94 USD on 20 November 2026, up 30.4% over 52 weeks. Its 52-week range is 9.230 USD to 17.07 USD: the price is 6.6% below the high and 72.7% above the low.
Its market capitalisation is 2.21B USD. It pays a dividend yielding 7.23%, against a median of 1.95% among the dividend payers in that peer group.
Perrigo Company reports return on equity of -48.6%, an operating margin of 5.5% and revenue down 5.2% year over year.
Its debt exceeds its cash by 3.03B USD, a debt-to-equity ratio of 1.24. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 18.00 USD is 12.9% above the current price. The next earnings report is expected on 25 February 2027.